Keywords: EU Ombudsman, Transparency, Pediatric medicines, Heart failure, Takeda, AstraZeneca, Blopress, Candesartan
EU Ombudsman wants more transparency concerning medicines for children
Article | 04 June 2012
European Union Ombudsman Nikiforos Diamandouros has called on the European Medicines Agency to increase the transparency of its procedures for ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
